CTOs on the Move

Progyny

www.progyny.com

 
Progyny is a transformative fertility, family building, and women`s health benefits solution, trusted by the nation`s leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients and physicians. Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women`s health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.progyny.com
  • 1359 Broadway 2nd Floor
    New York, NY USA 10018
  • Phone: 212.888.3124

Executives

Name Title Contact Details
Melissa Cummings
Executive Vice President, Chief Operating Officer Profile
Steven Leist
Chief Technology Officer Profile
Caleb O'Connell
Chief Information Security Officer Profile

Similar Companies

Keros Therapeutics

Keros Therapeutics is dedicated to the discovery and development of novel therapeutics for neuromuscular diseases

BioComm Network

BioComm Network is a Laguna Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Stolle Milk Biologics Inc

Stolle Milk Biologics Inc is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zymeworks

Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks` suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks` lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks` second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks` proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.

Omeros Corporation

Omeros Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.